Who Is a Good Candidate for Ketamine Therapy?

· Ketamine Therapy Directory Editorial Team
ketamine candidacy screening treatment safety
A clinician reviewing a patient chart during a ketamine therapy consultation

If you are researching ketamine therapy, one of the first things you probably want to know is whether it is even an option for you. The answer depends on your diagnosis, your treatment history, your medical profile, and the type of ketamine treatment being considered.

The short version: the strongest case for ketamine therapy is an adult with significant depression that has not responded well to standard treatments, who is medically stable enough to undergo supervised treatment and post-dose monitoring. But that is a starting point, not a final answer. Candidacy is determined by a qualified clinician after a thorough screening — not by a checklist on a website.

Here is what clinicians typically look at, what might rule you out, and what to expect when you go in for a consultation.

Ketamine therapy vs. esketamine: a quick distinction

Before getting into candidacy, it helps to understand that "ketamine therapy" is not one thing. There are two main paths:

Esketamine nasal spray (Spravato) is FDA-approved for treatment-resistant depression in adults and for depressive symptoms in adults with major depressive disorder who have acute suicidal ideation or behavior. It must be administered in a certified healthcare setting with at least two hours of monitoring after each dose.

IV or IM ketamine is used off-label for depression, anxiety, PTSD, chronic pain, and other conditions at specialized clinics and hospital programs. The FDA has stated explicitly that ketamine is not FDA-approved for any psychiatric disorder. That does not mean it is ineffective — it means the approval process and monitoring requirements differ.

Candidacy criteria overlap significantly between the two, but the specifics can vary depending on the treatment type and the clinic's own protocols.

Why people consider ketamine therapy

When standard treatments have not worked

Most people exploring ketamine therapy have already been through the conventional options — antidepressants, therapy, sometimes combinations of both — without enough improvement. This is the scenario that the clinical evidence supports most strongly. Johns Hopkins defines esketamine candidacy around having tried at least two antidepressants without adequate benefit, which is the clinical threshold for treatment-resistant depression.

Ketamine is not a first-line treatment. It is something clinicians consider when the usual approaches have fallen short.

When symptoms are severe and time matters

For some patients, the appeal of ketamine is its speed. Traditional antidepressants can take weeks to show results. Ketamine can produce noticeable changes within hours or days in some cases. For someone in acute distress — particularly someone with severe depressive symptoms and suicidal ideation — that timeline matters. The FDA approved Spravato partly on this basis, though it is worth noting that the labeling states its effectiveness in preventing suicide or reducing suicidal ideation has not been demonstrated.

Who may be a good candidate

A good candidate for ketamine therapy generally looks like this:

  • An adult with a depressive disorder being actively evaluated by a mental health professional
  • A history of limited response to at least two adequate antidepressant trials
  • Symptoms severe enough to justify a more intensive treatment option
  • Medical stability — no uncontrolled cardiovascular conditions, no active psychosis
  • Ability to attend repeated supervised visits — ketamine therapy is not a one-time event, and both the initial series and maintenance sessions require in-person attendance with post-treatment monitoring
  • Willingness to continue broader mental health care — ketamine works best as part of a treatment plan, not as a standalone shortcut

Some people also ask about ketamine for anxiety, PTSD, OCD, or chronic pain. These uses are more variable — often off-label, setting-specific, and supported by less definitive evidence than adult treatment-resistant depression. A good provider will be transparent about where the evidence is strong and where it is still developing.

Who may need extra screening

These are not automatic disqualifications. They are reasons a clinician will want to look more closely before proceeding.

Blood pressure and cardiovascular history

Ketamine temporarily raises blood pressure and heart rate. For most patients this is mild and resolves quickly, but for someone with uncontrolled hypertension, heart disease, or a history of stroke, even a brief spike can be risky. The Spravato prescribing information says clinicians should consider delaying treatment when baseline blood pressure is elevated and should avoid it when increases in blood pressure or intracranial pressure would pose a serious risk.

If your blood pressure is well-controlled with medication, treatment may still be possible — but expect your provider to coordinate with a cardiologist and monitor you more closely.

Psychosis, mania, or diagnostic complexity

The FDA labeling says patients with psychosis should be assessed carefully, with treatment started only if the benefit outweighs the risk. Active psychosis or schizophrenia is generally a contraindication. A history of bipolar disorder or mania requires careful evaluation because ketamine could potentially trigger manic episodes.

This does not mean every person with a complex psychiatric history is excluded. It means the clinician needs more information before making a decision.

Substance use history

Both the FDA and VA treatment protocols flag substance use history as requiring careful review. Ketamine has abuse and misuse potential, and someone with an active substance use disorder may face higher risks. Many clinics will want to understand the nature, recency, and severity of any substance use history before proceeding. Some protocols include urine toxicology screening.

A history of substance use does not automatically disqualify you. Active, moderate-to-severe substance use disorder is more likely to be a barrier.

Medication interactions

Certain medications warrant extra attention. CNS depressants — including benzodiazepines, opioids, and alcohol — can increase sedation risk when combined with ketamine. Psychostimulants and MAOIs can worsen blood pressure concerns. Your provider will review your full medication list and may need to adjust timing or dosages.

What may disqualify you

Spravato contraindications

The FDA lists specific contraindications for esketamine: aneurysmal vascular disease, arteriovenous malformation, and history of intracerebral hemorrhage. If you have any of these conditions, Spravato is not an option.

Common clinic-level exclusions

Individual clinics and hospital programs set their own additional criteria. A current VA national protocol, for example, excludes patients with schizophrenia or schizoaffective disorder, dementia, recent delirium, uncontrolled hypertension, severe cardiac decompensation, severe hepatic impairment, uncontrolled seizures, pregnancy, breastfeeding, current ketamine or esketamine abuse, or current moderate-to-severe substance use disorder.

Other clinics may have slightly different lists. The point is that screening criteria are real and vary by setting — which is why the consultation matters.

"Not now" does not always mean "never"

Some disqualifying factors are temporary. Uncontrolled blood pressure can be brought under control. An active substance use disorder can be stabilized. A pregnancy ends. If you are told you are not a candidate today, ask your provider what would need to change for the conversation to reopen.

Pregnancy, breastfeeding, and age

Is ketamine safe in pregnancy?

The FDA says Spravato is not recommended during pregnancy. Human data are insufficient, and animal studies have raised concerns about possible fetal harm. MotherToBaby notes that it is currently unknown whether ketamine increases the risk of birth defects or other pregnancy complications, while flagging concerns about fetal brain development from some data.

If you are pregnant, trying to conceive, or breastfeeding, discuss this with your provider before any treatment decision. The FDA labeling also says breastfeeding is not recommended during Spravato treatment.

How old do you have to be for ketamine therapy?

The FDA labeling states that safety and effectiveness of Spravato in pediatric patients have not been established. Research on ketamine for depression in adolescents exists but remains preliminary rather than definitive. Minors are not routinely treated, and when they are, it usually involves more specialized oversight and a higher bar for evaluation.

Adult use — generally 18 and older — is much more straightforward.

What happens during a ketamine consultation

If you decide to pursue an evaluation, here is what a typical screening process looks like, based on protocols used at VA medical centers and major hospital programs:

Mental health review. A psychiatric evaluation covering your diagnosis, symptom severity (often measured with a scale like the PHQ-9), treatment history, and suicide-risk assessment. The clinician is trying to confirm that your symptoms match the clinical profile for ketamine therapy and that you have genuinely exhausted other options.

Medical screening. Vital signs including blood pressure and heart rate. Review of your cardiovascular, cerebrovascular, and pulmonary history. Review of liver and kidney function. Sometimes a urine toxicology screen and pregnancy test.

Medication review. A full list of everything you take — prescription, over-the-counter, and supplements — to check for interactions with ketamine.

Informed consent. A detailed discussion of what the treatment involves, what side effects to expect, what the monitoring looks like, what the clinic's emergency protocols are, and what your responsibilities are (arranging a ride, fasting, follow-up). This is not a formality. It is your opportunity to ask questions and make sure you understand what you are agreeing to.

Questions to bring to your consultation

Going into a screening appointment with the right questions can help you evaluate both the treatment and the provider:

  • What diagnosis are you treating, and why do you think ketamine or esketamine fits my case?
  • Which type are you recommending — FDA-approved esketamine or off-label ketamine — and why?
  • Does my medical history raise any concerns, especially around blood pressure, heart issues, or liver function?
  • Does my psychiatric history require extra caution?
  • How do my current medications affect safety?
  • What screening will you do before my first treatment?
  • What side effects should I expect, and how long will monitoring last?
  • If I am pregnant, trying to conceive, or breastfeeding, what is your recommendation?
  • What happens if ketamine is not appropriate for me — what alternatives would you consider?

How to take the next step

If you think you might be a candidate, the path forward is a consultation with a provider who does formal screening. Look for a clinic or prescriber that conducts a thorough medical and psychiatric intake, monitors patients during and after treatment, has emergency protocols in place, and provides longitudinal follow-up — not just one-off sessions.

For esketamine specifically, treatment must occur in a certified healthcare setting under the REMS program. It is not a take-home medication.

Our directory lists ketamine therapy providers across the country. You can browse by location, clinic type, or treatment approach to find clinics near you that offer screening and supervised care.

Frequently asked questions

Who is a good candidate for ketamine therapy? Usually an adult with serious depression — often treatment-resistant depression — who has not improved enough with standard care and can safely complete supervised treatment and monitoring.

Who is not a good candidate for ketamine therapy? That depends on the treatment type and clinic, but major concerns include certain vascular conditions, uncontrolled blood pressure, active substance misuse, pregnancy, breastfeeding, active psychosis, and some complex medical or psychiatric histories.

What disqualifies you from ketamine therapy? For Spravato, FDA contraindications include aneurysmal vascular disease, arteriovenous malformation, and intracerebral hemorrhage. Many clinics also exclude patients with active psychosis, uncontrolled hypertension, severe liver impairment, or current moderate-to-severe substance use disorder. Protocols vary by setting.

Is ketamine safe in pregnancy? Spravato is not recommended during pregnancy. Human data are limited, and animal findings suggest possible fetal harm. Discuss pregnancy or plans to conceive with your provider before any treatment decision.

How old do you have to be for ketamine therapy? FDA labeling says Spravato safety and effectiveness have not been established in pediatric patients. Evidence for ketamine use in minors is still developing. Adult use — 18 and older — is the standard.

What happens during screening? Expect a psychiatric evaluation, treatment history review, medication check, suicide-risk assessment, vital signs, cardiovascular review, and sometimes urine toxicology or pregnancy testing.

Finding a provider

If you are ready to explore whether ketamine therapy is right for you, our directory lists clinics across the country. You can browse by location, clinic type, or condition treated to compare providers near you.

Related articles

Sources

Ketamine Therapy Directory Editorial Team

Content is researched using peer-reviewed medical literature, FDA publications, and clinical guidelines. This article is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider.